World's first clinical trial for anti-Abeta vaccine targeting Alzheimer's disease-like characteristics in people with Down syndrome
World's first clinical trial for anti-Abeta vaccine targeting Alzheimer's disease-like characteristics in people with Down syndrome
Jan 7, 2016
- Studies AC Immune's ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer's disease-like characteristics in people with Down syndrome
- Clinical Study is done in collaboration with University of California San Diego
- US NIH provides significant funding with an additional grant from the LuMind Research Down Syndrome Foundation
- Alzheimer's disease-like characteristics develop in virtually all people with Down syndrome over age 40; majority develops associated dementia over age 60